191018
1. 2. 3. 2
Rx =Prescription Drug NEC =New Chemical Entity GE =Generic Drug OTC =Over The Counter 3
04
5
23 35 510 23 6
R&D 7
8
2005 ( best in class ) MR power marketing HMG-CoA 12,963 6,223 Ca ++ 5,245 4,633 3,707 2005 9
10
1. 2. 1. 2. DNAsiRNA 11
11981 12
Bcr-Abl () CML (EGFR) Bcr-ABLBcrAbl 13
1. 2. 3. 14
15
2000 2007 () () () 349 16 228 105 26 7 (4.6) (65.3) (30.1) 16
1. 2. 3. 4. 5 4. 6. 200710 17
Q. 18
Q. 19
Q. 46 44 2 0 19 23 4 40 6 0 18 23 5 37 7 2 18 22 6 28 18 0 13 26 7 22 20 4 8 29 9 22 17 7 6 25 15 =465 20
58 p 101 p 112 p 1)~3) 21
22
CMC 23
% 6,000 570 4159 9.5 24
1. 2. 3. 25
58 10 58 1980 2005 2015 5-8 5-8 5-8 2-5 6-9 8-11 26
(%) 100 80 60 40 20 C MRSA IBS COPD 0 0 20 40 60 80 100(%) 17HS 27
POC (Phase) 28
AK 29